Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction.

Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Peterson ED, Fonarow GC, Curtis LH.

JAMA. 2012 Nov 28;308(20):2097-107. doi: 10.1001/jama.2012.14795.

PMID:
23188026
2.

Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.

Wang TY, Vora AN, Peng SA, Fonarow GC, Das S, de Lemos JA, Peterson ED.

J Am Heart Assoc. 2016 Jan 21;5(1). pii: e002612. doi: 10.1161/JAHA.115.002612.

3.

Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.

Khazanie P, Liang L, Curtis LH, Butler J, Eapen ZJ, Heidenreich PA, Bhatt DL, Peterson ED, Yancy CW, Fonarow GC, Hernandez AF.

Circ Heart Fail. 2016 Feb;9(2):e002444. doi: 10.1161/CIRCHEARTFAILURE.115.002444.

4.

Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure.

Curtis LH, Mi X, Qualls LG, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC.

Am Heart J. 2012 Jun;163(6):946-953.e1. doi: 10.1016/j.ahj.2012.03.007. Epub 2012 May 9.

PMID:
22709746
5.

Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure.

Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC.

Am Heart J. 2013 Jun;165(6):979-986.e1. doi: 10.1016/j.ahj.2013.03.007. Epub 2013 Apr 18.

PMID:
23708170
6.

Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation.

Hernandez AF, Liang L, Fonarow GC, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Qualls LG, Al-Khatib SM, Piccini JP, Curtis LH.

Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):670-9. doi: 10.1161/CIRCOUTCOMES.113.000632. Epub 2014 Sep 9.

7.

Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure.

Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, Fairclough DL, Rumsfeld JS, Masoudi FA, Magid DJ.

Circ Heart Fail. 2014 Jan;7(1):43-50. doi: 10.1161/CIRCHEARTFAILURE.113.000709. Epub 2013 Nov 26.

8.

Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction.

Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A.

JACC Heart Fail. 2013 Feb;1(1):40-7.

9.

In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.

Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L; IN HF Outcome Investigators.

Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22.

PMID:
24630337
10.

Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).

Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B; EMPHASIS-HF Investigators.

J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27.

11.

Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction.

Eapen ZJ, Greiner MA, Fonarow GC, Yuan Z, Mills RM, Hernandez AF, Curtis LH.

Am Heart J. 2014 Mar;167(3):369-375.e2. doi: 10.1016/j.ahj.2013.12.001. Epub 2013 Dec 11.

PMID:
24576522
12.

Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.

Lund LH, Benson L, Dahlström U, Edner M.

JAMA. 2012 Nov 28;308(20):2108-17. doi: 10.1001/jama.2012.14785.

PMID:
23188027
13.

Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml/min/1.73 m(2.).

Inampudi C, Parvataneni S, Morgan CJ, Deedwania P, Fonarow GC, Sanders PW, Prabhu SD, Butler J, Forman DE, Aronow WS, Allman RM, Ahmed A.

Am J Cardiol. 2014 Jul 1;114(1):79-82. doi: 10.1016/j.amjcard.2014.03.062. Epub 2014 Apr 18.

14.

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Khazanie P, Hellkamp AS, Fonarow GC, Bhatt DL, Masoudi FA, Anstrom KJ, Heidenreich PA, Yancy CW, Curtis LH, Hernandez AF, Peterson ED, Al-Khatib SM.

J Am Heart Assoc. 2015 Aug 6;4(8):e002061. doi: 10.1161/JAHA.115.002061.

15.

Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors.

Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL.

Am J Med. 2000 Dec 1;109(8):605-13.

PMID:
11099679
16.

Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.

Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M.

Pharmacotherapy. 2016 Feb;36(2):174-86. doi: 10.1002/phar.1701. Epub 2016 Feb 3.

PMID:
26841333
17.

Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.

Bhatia V, Bajaj NS, Sanam K, Hashim T, Morgan CJ, Prabhu SD, Fonarow GC, Deedwania P, Butler J, Carson P, Love TE, Kheirbek R, Aronow WS, Anker SD, Waagstein F, Fletcher R, Allman RM, Ahmed A.

Am J Med. 2015 Jul;128(7):715-21. doi: 10.1016/j.amjmed.2014.11.036. Epub 2014 Dec 30.

PMID:
25554369
18.

Relationships between emerging measures of heart failure processes of care and clinical outcomes.

Hernandez AF, Hammill BG, Peterson ED, Yancy CW, Schulman KA, Curtis LH, Fonarow GC.

Am Heart J. 2010 Mar;159(3):406-13. doi: 10.1016/j.ahj.2009.12.024.

19.

Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.

Sanam K, Bhatia V, Bajaj NS, Gaba S, Morgan CJ, Fonarow GC, Butler J, Deedwania P, Prabhu SD, Wu WC, White M, Love TE, Aronow WS, Fletcher RD, Allman RM, Ahmed A.

Am J Med. 2016 Oct;129(10):1067-73. doi: 10.1016/j.amjmed.2016.05.008. Epub 2016 Jun 2.

PMID:
27262781
20.

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.

Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, Hernandez AF, Butler J, Yancy CW, Fonarow GC.

Am Heart J. 2014 Nov;168(5):721-30. doi: 10.1016/j.ahj.2014.07.008. Epub 2014 Jul 22.

PMID:
25440801

Supplemental Content

Support Center